A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia

Zhu, Lixia; Chen, Rongrong; Wang, Lulu; Sun, Jianai; Zhou, De; Li, Li; Qian, Jinwen; Zhang, Yi; Tong, Hongyan; Yu, Wenjuan; Meng, Haitao; Mai, Wenyuan; Shi, Yuanfei; Jin, Jie; Ye, Xiu-Jin; Zhu, Hong‐Hu

doi:10.1007/s00520-022-07126-y

Cited by 8 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the studies by Kim et al [9] and Mendes et al [10] showed bacteremia after hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation. With our patient on venetoclax, neutropenia almost always occurs (84%), and microbiologically documented infections (30.5%) are commonly seen [12]. However, the literature has never reported C. sputigena infection of the tonsils.…”

Section: Discussionmentioning

confidence: 65%

Capnocytophaga sputigena Tonsillitis in a Patient With Acute Myeloid Leukemia

Heh,

Allen,

Raynor

et al. 2024

Cureus

View full text Add to dashboard Cite

Capnocytophaga sputigena is a gram-negative facultatively anaerobic, capnophilic bacterium typically residing in the human oropharyngeal flora. This opportunistic pathogen can cause a wide range of infections, from bacteremia to septic abortion. However, it is exceedingly rare for a patient to present with tonsillitis due to C. sputigena. Herein, we discuss the presentation, hospital course, and clinical trajectory of a patient experiencing complications of tonsillitis related to C. sputigena in the context of acute myeloid leukemia. Additionally, we delve into the treatment approaches and challenges in managing this particular pathogen.

show abstract

Section: Discussionmentioning

confidence: 65%

Capnocytophaga sputigena Tonsillitis in a Patient With Acute Myeloid Leukemia

Heh,

Allen,

Raynor

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Therefore, our experience suggested that AZA/ VEN may be a possible cure-oriented treatment approach also in the difficult-to-treat setting, rather than palliative and life-prolonging intents only. Moreover, the lack of adverse effects, particularly of infectious complications [15] as well as the disappearance of NPM1 mutation may drive the continuation of therapy in order to maintain the longest possible molecular response which may translate in improving patient's survival and quality of life.…”

Section: Discussionmentioning

confidence: 99%

Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient

Niscola¹,

Mazzone²,

Fratoni³

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Surprisingly, most patients had VEN dose reductions or cycle delays, primarily due to therapy-related toxicities. Zhu, L.X., et al reported that thirty-two out of 59 patients experienced VEN schedule delay and 71.2% of patients experienced VEN dose reduction due to hematological and infectious adverse events (AEs) [5]. Similarly, in Mayo Clinic series, they observed VEN treatment cycle delays were frequently encountered in roughly half of patients and VEN dose reduction were explored in 70% of the patients[6].…”

Section: Introductionmentioning

confidence: 99%

Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid Leukemia

Cui

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

venetoclax (VEN) and Azacitidine (AZA) combination have shown improved survival and excellent responses in patients with untreated Acute myeloid leukemia (AML). However, frequent dose reduction (or discontinuation) occurred due to therapy-related toxicity and may limit triplet combination tolerance. This study retrospectively analyzed the characteristics and outcomes of newly diagnosed AML patients who received 100mg VEN for 14 days combined with AZA at our institution. Overall, 36 patients were enrolled, the median age at diagnosis was 64 years; after a median follow-up of 15(range 4–29) months, median overall survival (OS) and progression-free survival (PFS) for the total cohort were 17 (4–29) months and 12 (1–28) months, and for patients achieving composite complete remission (CRc) were not reached. Overall response rate (ORR) was 69.4% and CRc rate were 66.7% for the total cohort. Subgroup analysis revealed that NPM1 mutations and FAB-M5 were associated higher response rates, while adverse ELN risk group predicted inferior response. ASXL1, NPM1 and IDH1/2 mutation was statistically significant impact the PFS duration. The most common adverse events were hematological, with grade 3 or 4 neutropenia, thrombocytopenia, and anemia reported in 36%, 25%, 44% of patients, respectively. In summary, the VEN combination regimen remains effective for newly diagnosed AML in the real world despite VEN dose reductions.

show abstract

A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia

Cited by 8 publications

References 28 publications

Capnocytophaga sputigena Tonsillitis in a Patient With Acute Myeloid Leukemia

Capnocytophaga sputigena Tonsillitis in a Patient With Acute Myeloid Leukemia

Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient

Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid Leukemia

Contact Info

Product

Resources

About